Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus:

An Introduction to Bromocriptine QR

Log in or subscribe to view full content.
Article is also available for purchase the article in one of the available formats.
David S. H. Bell, MB, FACP, FACE

Table of Contents

Postgraduate Medicine:

Volume 124 No. 5


Clinical Features

Purchase this article in one of the formats specified below:

DOI: 10.3810/pgm.2012.09.2598
Abstract: Cardiovascular risk reduction is a key priority in patients with diabetes. The relationship between glycemic control and macrovascular outcomes, such as the benefit of intensive glucose control and the importance of postprandial or fasting blood glucose, is still under debate. A number of pharmacologic options are available to treat type 2 diabetes mellitus and these options have differing evidence for their cardiovascular safety. In this article, the novel agent bromocriptine quick release is discussed. Recently approved, this once-daily treatment provides glycemic control as monotherapy or in combination with other antihyperglycemic medications and has been shown in a prospective phase 3 safety study to not increase cardiovascular risk. Therefore, bromocriptine quick release increases the range of options available to treat patients with type 2 diabetes mellitus without increasing cardiovascular risk.

Keywords: bromocriptine QR; type 2 diabetes mellitus; cardiovascular risk; glycemic control